Reviva Pharmaceuticals Holdings, Inc.
RVPHDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How RVPH's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brilaroxazine | Phase 3 | Schizophrenia | - | - |
RP5063 | Phase 2 | Acute Schizophrenia | - | - |
Frequently asked questions
What is in Reviva Pharmaceuticals Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Reviva Pharmaceuticals Holdings, Inc.'s (RVPH) pipeline across Phase 3, Phase 2. Its lead program is Brilaroxazine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Reviva Pharmaceuticals Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Reviva Pharmaceuticals Holdings, Inc. (RVPH) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RVPH biotech catalysts?→
Add RVPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Reviva Pharmaceuticals Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.